Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03431090 · ClinicalTrials.gov registry record · Phase 1
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia
A Phase 1 study of Hematologic Malignancy and Myelodysplasia, sponsored by Nationwide Children's Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03431090 is a Phase 1 study of Hematologic Malignancy and Myelodysplasia that is active but no longer recruiting, run by Nationwide Children's Hospital. The registered enrollment target is 20 participants, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03431090, a Phase 1 study of Hematologic Malignancy and Myelodysplasia, is active but no longer recruiting, sponsored by Nationwide Children's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+ cell depleted graft.
Conditions Studied
Interventions
- DEVICE CliniMACS® TCRαβ/CD19 Combined Depletion System
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-03-02 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03431090
The ClinicalTrials.gov registry entry for NCT03431090 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 228-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (91% lower). The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which CliniMACS® TCRαβ/CD19 Combined Depletion System is the first listed.
NCT03431090 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03431090 about?
NCT03431090 is a clinical study titled "Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia". This is a Phase I/II study designed to evaluate the kinetics of hematopoietic reconstitution and the incidence of acute chronic GVHD after partially matched related donor hematopoietic cell transplantation using an αβTCR/CD19+ cell depleted graft.
What is the current status of trial NCT03431090?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2018-03-02. Estimated completion is 2026-01.
What conditions does trial NCT03431090 study?
This clinical trial studies the following conditions: Hematologic Malignancy, Myelodysplasia.
What interventions are being tested in trial NCT03431090?
The interventions under investigation include: CliniMACS® TCRαβ/CD19 Combined Depletion System (DEVICE).
Who is sponsoring clinical trial NCT03431090?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03431090 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
RECRUITING · Phase 1
-
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.